Investigations on cellular ingestion, particularly quantitative and qualitative revealed that SalB cytoplasmic abundance was much greater after HN30 and HN13 were treated with SalB-PLC NPs as compared to normal SalB. Cell death activation and cell cycle inhibition were equally reported in the HNSCC cells that had been challenged to SalB-PLC NPs. This evidence concerns the gene HSPG2 and head and neck squamous cell carcinoma.